Status:

UNKNOWN

Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids

Lead Sponsor:

Pierre Fabre Dermo Cosmetique

Collaborating Sponsors:

University Paul Sabatier of Toulouse

University Hospital, Geneva

Conditions:

Cortico Atrophy

Eligibility:

All Genders

50+ years

Phase:

PHASE3

Brief Summary

Methodology :Phase III study, single centre, double blind, versus excipient, randomised, controlateral design. Selection of the patients :Number of subjects required 60 : * 30 patients needing an or...

Detailed Description

Study conduct Two steps for each patient: 1. the first step lasting 3 months : assessment of changes in mechanisms involved in ACIC with the RV3391A cream (M0 à M3). At the beginning of the corticot...

Eligibility Criteria

Inclusion

  • Patients needing an oral corticotherapy:
  • aged over 50 years
  • first corticotherapy over 0.5 mg/kg/day
  • expectable period with a corticotherapy over 10 mg/day more than 3 months
  • having signed a written informed consent form
  • registered with a social security or health insurance system
  • Patients needing a topical corticotherapy:
  • aged over 50 years
  • topical corticotherapy with a high or very high potency corticoid over 10 g/day
  • expectable period with a topical corticotherapy more than 3 months
  • having signed a written informed consent form
  • registered with a social security or health insurance system

Exclusion

  • Oral or topical corticotherapy within the last 3 months
  • Cutaneous inflammation on the anterior side of the forearm
  • Medical history of psychosis induced by corticotherapy
  • Medical history of allergy to RV3391A product its and excipients.
  • Medical history of allergy to mineral cream Avene SPF50 excipients.
  • Medical history of allergy to latex, surgical tape, chlorhexidine, lidocaine or xylocaine
  • Clotting disorder or anticoagulant intake
  • Healing disorder
  • Women who are not post-menopausal women
  • Substitutive estrogenotherapy for less than 6 months
  • Impossibility to be registered in the Volunteers National Register
  • Inability to comply with requirements of the clinical monitoring program,
  • Inability to personally sign the informed consent form
  • Is deprived of his freedom by an administrative or judicial decision; or who is under guardianship or protective custody

Key Trial Info

Start Date :

June 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2010

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00709579

Start Date

June 1 2008

End Date

August 1 2010

Last Update

July 8 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre Hopitalier Universitaire de Toulouse

Toulouse, France, 31052